NCT00045786View on ClinicalTrials.gov

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

December 31, 2001

Study Completion Date

November 30, 2003

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

CC-1088

400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)

Trial Locations (1)

60612-3515

Rush-Presbyterian-St Luke's Medical Center, Chicago